In 1969, pathologist Kilmer McCully autopsied the brains and arteries of two children who had died of homocystinuria — a rare genetic condition causing extremely elevated homocysteine — and noticed something unexpected: their arteries showed severe atherosclerotic changes despite their very young age and low cholesterol. McCully proposed a radical hypothesis: that elevated homocysteine, not cholesterol, was a primary driver of vascular disease.
The medical establishment spent the next two decades largely dismissing this idea. McCully was eventually forced out of Harvard. Then the data began to accumulate. Large population studies, Mendelian randomisation analyses, and clinical trials of B vitamin supplementation generated a body of evidence that now firmly establishes homocysteine as an independent cardiovascular risk factor — and, particularly for brain health, one of the most important and most treatable biomarkers available.
Despite this, homocysteine remains poorly tested in routine clinical practice. A 2026 survey of UK GPs found that fewer than 15% routinely include homocysteine in cardiovascular risk assessments. In the United States, it is almost never included in standard preventive panels. This represents a significant missed opportunity, because the treatment for the most common cause of elevated homocysteine — B12 and folate deficiency — is cheap, safe, and highly effective.
The Methylation Cycle: Where Homocysteine Comes From
To understand why homocysteine accumulates and what it signals, it helps to understand the biochemical cycle in which it participates: the methionine cycle, also called the one-carbon metabolism pathway or the methylation cycle.
The cycle begins with methionine, an essential amino acid obtained from dietary protein. Methionine is converted to S-adenosylmethionine (SAM) — often called the body's universal methyl donor. SAM donates a methyl group (-CH₃) to an enormous range of cellular substrates: DNA methylation (epigenetic regulation), synthesis of phosphatidylcholine (a critical membrane phospholipid), methylation of neurotransmitters (noradrenaline to adrenaline, serotonin metabolism), synthesis of creatine, and hundreds of other reactions.
After donating its methyl group, SAM becomes S-adenosylhomocysteine (SAH), which is hydrolysed to release homocysteine. At this point, homocysteine reaches a metabolic junction with two exit routes:
Route 1 — Remethylation: Homocysteine receives a methyl group from 5-methyltetrahydrofolate (5-MTHF, active folate), regenerating methionine. This reaction requires vitamin B12 as a cofactor for the enzyme methionine synthase. When B12 or folate is insufficient, this route is impaired and homocysteine accumulates.
Route 2 — Transsulfuration: Homocysteine combines with serine, catalysed by cystathionine beta-synthase (CBS), to form cystathionine. This requires vitamin B6 (pyridoxal 5'-phosphate, P5P) as a cofactor. Cystathionine is further converted to cysteine and ultimately to glutathione — the body's master antioxidant. When B6 is insufficient, or when the transsulfuration rate cannot keep pace with homocysteine production, homocysteine accumulates.
A third remethylation pathway uses betaine (trimethylglycine, TMG) as the methyl donor through the enzyme betaine-homocysteine methyltransferase (BHMT), primarily in the liver. This pathway is B12/folate-independent and is the basis for using TMG as a therapeutic supplement to lower homocysteine.
Homocysteine and the Cardiovascular System
The vascular toxicity of elevated homocysteine operates through several well-characterised mechanisms, making it qualitatively different from cholesterol-based atherogenesis:
Endothelial dysfunction: Homocysteine is directly toxic to vascular endothelial cells. It impairs nitric oxide production, reduces endothelial repair capacity, and promotes endothelial apoptosis. Elevated homocysteine is consistently associated with impaired flow-mediated dilation — a sensitive marker of endothelial function — even at levels considered 'borderline' by standard laboratory ranges.
Oxidative stress: Homocysteine auto-oxidises in plasma, generating reactive oxygen species (superoxide and hydrogen peroxide) that further damage endothelial cells, oxidise LDL, and deplete antioxidant defences.
Prothrombotic effects: Homocysteine activates platelets, impairs anticoagulant mechanisms (particularly protein C activation), and promotes expression of procoagulant factors on endothelial surfaces. This thrombotic tendency makes hyperhomocysteinaemia particularly dangerous for stroke risk.
Smooth muscle proliferation: Homocysteine stimulates vascular smooth muscle cell proliferation and collagen production, contributing to arterial stiffening and plaque growth.
| Homocysteine Level | Clinical Category | Approximate Relative Risk |
|---|---|---|
| < 7 µmol/L | Optimal | Baseline (lowest risk) |
| 7–10 µmol/L | Acceptable | Mild elevation above optimal |
| 10–15 µmol/L | Borderline high | ~1.3–1.5× increased CV risk; elevated dementia risk |
| 15–30 µmol/L | Moderate hyperhomocysteinaemia | ~2× cardiovascular event risk; substantially elevated dementia risk |
| > 30 µmol/L | Severe hyperhomocysteinaemia | Very high risk; consider inborn errors / severe deficiency |
The epidemiological data is substantial. A landmark 1995 meta-analysis in JAMA by Boushey and colleagues analysed 27 studies involving over 4,000 patients with coronary, cerebrovascular, or peripheral arterial disease and found that each 5 µmol/L increase in homocysteine was associated with a relative risk of coronary artery disease of 1.6 in men and 1.8 in women — comparable to the effect of a 20 mg/dL increase in total cholesterol. More recent meta-analyses, including a 2012 Cochrane-level analysis of over 20,000 subjects, consistently find 25–35% increases in cardiovascular risk per 5 µmol/L elevation.
Homocysteine and Brain Health: The Strongest Evidence
While the cardiovascular data is strong, the evidence linking homocysteine to brain atrophy and dementia risk may be even more compelling — and the intervention data is considerably more positive here than for cardiovascular outcomes.
Multiple large prospective cohort studies have found that elevated homocysteine is one of the strongest modifiable predictors of cognitive decline and Alzheimer's disease:
The Framingham Heart Study found that plasma homocysteine above 14 µmol/L was associated with a near doubling (1.8×) of the risk of dementia and Alzheimer's disease over 8 years of follow-up. This association persisted after adjustment for age, sex, education, BMI, blood pressure, and cardiovascular disease.
The VITACOG trial (Oxford University, 2010) randomised 168 adults with mild cognitive impairment and elevated homocysteine to high-dose B vitamins (folic acid 0.8 mg, B6 20 mg, B12 0.5 mg) or placebo for 2 years. MRI brain scans showed that the B vitamin group had 53% less brain atrophy compared to placebo — a striking structural outcome. Subgroup analysis found that the benefit was most pronounced in participants with baseline homocysteine above 11.3 µmol/L. A subsequent analysis found that the brain atrophy reduction was concentrated in regions particularly affected in Alzheimer's disease (medial temporal lobe, parahippocampal gyrus).
The mechanistic pathways linking homocysteine to neurodegeneration are multiple: direct neuronal excitotoxicity (homocysteine activates NMDA receptors, causing calcium influx and neuronal death at high concentrations), impaired DNA methylation (SAM depletion resulting from methylation cycle impairment reduces epigenetic maintenance), reduced myelin synthesis (myelin maintenance requires SAM-dependent methylation reactions), and vascular contributions through the endothelial damage mechanisms described above.
Common Causes of Elevated Homocysteine
In clinical practice, the most common causes of elevated homocysteine are nutritional and pharmacological — highly treatable causes that should be identified before concluding that elevation reflects an irreducible genetic risk:
Vitamin B12 deficiency is the most prevalent cause in clinical practice. B12 absorption requires gastric acid (for release from food protein) and intrinsic factor (for ileal absorption). Both decline with age, making B12 deficiency extraordinarily common in adults over 60 — affecting an estimated 20–40% by sensitive markers. Vegans and strict vegetarians are at high risk since B12 is found only in animal products. Metformin use reduces B12 absorption through a well-characterised ileal mechanism — up to 30% of long-term metformin users develop B12 deficiency. Proton pump inhibitors reduce gastric acid and impair B12 release from dietary protein.
Folate deficiency impairs the remethylation of homocysteine via the B12-dependent methionine synthase reaction. In countries with folic acid food fortification (US, Canada, parts of Europe), gross folate deficiency is uncommon, but functional folate insufficiency — particularly in individuals with MTHFR C677T who cannot efficiently process standard folate into methylfolate — remains prevalent.
MTHFR polymorphisms, particularly the C677T homozygous genotype (present in 10–15% of Europeans), impair the conversion of folate to 5-MTHF, the active form needed for remethylation. These individuals require methylfolate (5-MTHF) supplementation rather than folic acid, which they cannot efficiently process.
Renal insufficiency impairs homocysteine clearance through renal tubular mechanisms. Even mild CKD (eGFR below 60) substantially elevates homocysteine, and in end-stage renal disease values can exceed 25–30 µmol/L. Renal function should be checked in any patient with unexplained homocysteine elevation.
Hypothyroidism reduces homocysteine clearance through impaired renal function and reduced methionine synthase activity. Treating the hypothyroidism often normalises homocysteine. TSH should be included in the workup of elevated homocysteine.
Advancing age independently increases homocysteine through declining B12 absorption, declining renal function, and reduced enzyme kinetics. Mean homocysteine rises from approximately 8–9 µmol/L in young adults to 12–15 µmol/L in adults over 70, which partly explains the increasing dementia risk with age.
The Controversy: Does Lowering Homocysteine Reduce Events?
The clinical trial evidence on B vitamin supplementation for cardiovascular outcomes is genuinely mixed, and it is important to understand why before dismissing homocysteine as merely an epiphenomenon.
The HOPE-2 trial (2006), which randomised over 5,500 patients with established cardiovascular disease to high-dose B vitamins (folic acid 2.5 mg, B12 1 mg, B6 50 mg) or placebo, found no significant reduction in the primary endpoint of death, myocardial infarction, or stroke over 5 years — despite successfully lowering homocysteine by ~3 µmol/L. Similar null results came from VISP and NORVIT.
The interpretation of these trials requires care. HOPE-2 was conducted primarily in North America after folic acid fortification, meaning baseline homocysteine was already lower than in unfortified populations, and the headroom for B vitamin benefit may have been limited. All three trials enrolled patients with established cardiovascular disease, where pre-existing plaque burden is extensive — the therapeutic window for preventing new events through endothelial improvement may be narrow. Furthermore, the doses used (particularly synthetic folic acid) may have been suboptimal for individuals with MTHFR variants.
In contrast, meta-analyses in populations without folic acid fortification show more positive cardiovascular effects of B vitamin supplementation. The Chinese CSPPT trial (2015), conducted in a population without folic acid fortification and with very high MTHFR TT prevalence, found that folic acid supplementation alongside antihypertensive therapy significantly reduced first stroke compared to antihypertensive therapy alone.
For cognitive outcomes, as detailed above, the VITACOG trial and subsequent analyses provide strong evidence of benefit in people with elevated baseline homocysteine.
Treatment: B Vitamins and Beyond
The therapeutic approach to elevated homocysteine is guided by identifying the underlying cause and addressing it with targeted supplementation:
Methylcobalamin (active B12) at 1–2 mg daily (or 1 mg sublingual) is preferred over cyanocobalamin for individuals with absorption concerns, renal impairment, or MTHFR variants. Sublingual or injectable administration bypasses the need for intrinsic factor and gastric acid, making it effective even in people with gastric atrophy or PPI use.
L-Methylfolate (5-MTHF) at 400–1000 µg daily is preferred over folic acid for anyone with known or suspected MTHFR C677T homozygous genotype. 5-MTHF is the biologically active form that bypasses the MTHFR enzymatic step entirely. Folic acid must be converted to 5-MTHF through a 4-step process partly dependent on the MTHFR enzyme — and in TT individuals, this conversion is severely impaired.
Pyridoxal 5'-phosphate (P5P) at 25–50 mg daily is the active form of vitamin B6 and supports the transsulfuration pathway. P5P is preferred over pyridoxine HCl for supplementation because it does not require hepatic phosphorylation to become active.
Betaine (trimethylglycine, TMG) at 500–3000 mg daily provides an alternative methyl donor through the BHMT pathway, lowering homocysteine independently of B12 and folate. This is particularly valuable in individuals who do not fully respond to B vitamin supplementation alone, or in those with chronic illness or high protein intake who have increased homocysteine production rates.
Most people with nutritional causes of elevated homocysteine respond within 6–12 weeks of supplementation, with homocysteine reductions of 25–50% achievable. Retesting at 8–12 weeks after initiating treatment is recommended to assess response.
How to Test Homocysteine
Homocysteine is available through all major commercial laboratories as a standard blood test. It requires a fasting blood draw (protein-rich meals can raise homocysteine by 10–20% transiently). The test costs approximately $20–50 self-pay and is covered by most insurance plans with appropriate clinical indication.
For a complete methylation status assessment, the following panel provides comprehensive information:
- Homocysteine (fasting)
- Serum B12 (note: normal serum B12 does not exclude functional deficiency)
- Methylmalonic acid (MMA) — a more sensitive marker of functional B12 status
- Serum folate
- RBC folate (reflects longer-term tissue folate status)
- TSH (to exclude hypothyroidism)
- eGFR / creatinine (to assess renal function)
- MTHFR C677T and A1298C genotyping (if available)
Testing frequency: annual for anyone with a known elevated level or on treatment; inclusion in a comprehensive preventive panel at baseline and every 2–3 years in adults over 40 is a sensible standard.
The Bottom Line
Homocysteine is inexpensive to measure, commonly elevated, mechanistically plausible as a vascular and neurotoxin, and in the majority of cases highly treatable with safe, cheap B vitamin supplementation. The evidence linking elevated homocysteine to cardiovascular events is substantial; the evidence linking it to brain atrophy and dementia risk in people with known elevation is striking.
The current standard of care — essentially ignoring homocysteine until it appears in the context of an unexplained thrombosis or stroke workup — reflects institutional inertia more than clinical evidence. Every adult should know their homocysteine level. If yours is above 10 µmol/L, investigate and treat. The intervention is often nothing more than appropriate B12 and methylfolate supplementation — a few dollars a month with a potentially significant payoff for brain longevity.